OpenOnco
UA EN
Plan Builder Onco Wiki Tumor Board
OpenOnco · DIS-IMT · Elderly / frail patient (age 78, ECOG 3)
← Back to galleryFeedback on this case
OpenOnco · Treatment Plan
Treatment plan — Inflammatory myofibroblastic tumor
PLAN-VAR-IMT-FRAIL-V1 · v1 · 2026-05-12
Patient
VAR-IMT-FRAIL · Algorithm: ALGO-IMT-1L
DiagnosisInflammatory myofibroblastic tumor
MOH / ICD-10D48.1
ICD-O-38825/1; C76, C16, C25, C34, C49, C56

Clinical significance of mutations (ESCAT)

Tumor-board context — the engine does not use these tiers to rank tracks
✅ Covered biomarkers (matched in KB)
BiomarkerVariantESCATEvidenceClinical significanceDrugsSources
No clinically actionable variants matched in this profile.
⚠️ Not included in plan
BiomarkerStatus
BIO-ALK-FUSIONBIO definition in KB; no ESCAT BMA entry — verify with clinician

Primary current-line option

Standard plan
★ DEFAULT
Indication
IND-IMT-ALK-CRIZOTINIB
Regimen
Crizotinib monotherapy (ALK-fusion-positive inflammatory myofibroblastic tumor)
Drugs + NSZU
  • Crizotinib (DRUG-CRIZOTINIB) 250 mg PO BID, continuous · Per regimen schedule · IV ⚠ NSZU — not for this indication
Reason
Primary current-line option selected by ALGO-IMT-1L at the fallback path.

Timeline

Treatment timeline — derived from regimen + monitoring schedule

Standard plan

Induction · Crizotinib monotherapy (ALK-fusion-positive inflammatory myofibroblastic tumor)
21-day cycles × 6 cycles or until progression / toxicity

MDT brief

MDT talk tree (2 steps)

#OwnerTopicAction
1molecular_geneticistSpecialist review Indication references an actionable genomic biomarker — mutation / target / actionability interpretation needed.
2palliative_careSpecialist review Reduced performance status / decompensated comorbidity — goals-of-care assessment needed.

Skills (recommended) — for consideration (2)

  • Molecular geneticist / molecular oncologist recommended
    Indication references an actionable genomic biomarker — mutation / target / actionability interpretation needed.
  • Palliative care recommended
    Reduced performance status / decompensated comorbidity — goals-of-care assessment needed.

Data quality

Usable with caveats. No critical default-track gap was found, but the MDT should review the listed caveats before final sign-off.
  • Biomarker coverage: 1/1 known (100%), 0 missing, 0 default-track gaps
  • Unevaluated RedFlags: RF-IMT-FRAILTY-AGE, RF-IMT-HIGH-RISK-BIOLOGY, RF-IMT-INFECTION-SCREENING, RF-IMT-ORGAN-DYSFUNCTION, RF-IMT-TRANSFORMATION-PROGRESSION
Technical MDT skill metadata (2/16 activated in this plan)
All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).
Specialistskill_idVersionLast reviewedSign-offsDomain
Cellular therapy specialist (CAR-T)cellular_therapy_specialistv0.1.02026-04-250cellular_therapy
Clinical pharmacistclinical_pharmacistv0.1.02026-04-250clinical_pharmacy
Hematologist / oncohematologisthematologistv0.1.02026-04-250hematology_oncology
Hematopathologist (lymphoma / leukemia / myeloma)hematopathologistv0.1.02026-04-250hematopathology
Infectious disease / hepatologyinfectious_disease_hepatologyv0.1.02026-04-250infectious_diseases
Medical oncologist (solid-tumor chemotherapist)medical_oncologistv0.1.02026-04-250solid_oncology
Molecular geneticist / molecular oncologistmolecular_geneticistv0.1.02026-04-250molecular_oncology
Palliative carepalliative_carev0.1.02026-04-250palliative_care
Pathologist (general)pathologistv0.1.02026-04-250pathology
Primary care / family physicianprimary_carev0.1.02026-04-250primary_care
Psycho-oncologistpsychologistv0.1.02026-04-250psychosocial
Radiation oncologistradiation_oncologistv0.1.02026-04-250radiation_oncology
Radiologistradiologistv0.1.02026-04-250diagnostic_imaging
Social worker / case managersocial_worker_case_managerv0.1.02026-04-250psychosocial
Surgical oncologistsurgical_oncologistv0.1.02026-04-250surgical_oncology
Transplant specialist (BMT)transplant_specialistv0.1.02026-04-250cellular_therapy

Sources cited

Experimental options (clinical trials)

Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-05-12.
NCTTitlePhaseStatusSponsorUASignalsEligibility (excerpt)
NCT04094610A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsPHASE1 / PHASE2RECRUITINGTurning Point Therapeutics, Inc.—Surrogate endpoint only

Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.

Option availability in Ukraine

Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).
OptionUA registrationNSZUCost orientationAccess pathway
Standard plan
Crizotinib monotherapy (ALK-fusion-positive inflammatory myofibroblastic tumor) (REG-CRIZOTINIB-IMT)
✓ registered✓ covered₴-? — verify pathwayNSZU formulary
Trial · NCT04094610
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
No UA site listed — international referral required
— unknown— unknown
self-pay: ₴0/course
Trial sponsor

Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-05-12.

plan_id: PLAN-VAR-IMT-FRAIL-V1 | version: 1 | generated: 2026-05-12T18:41:26.459918+00:00
Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.
Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.
This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.